Welcome to MolDiag-PaCa
Cyclacel (www.cyclacel.com) is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. The company has two clinical-stage compounds, seliciclib (CYC202) and sapacitabine. Seliciclib is an orally-available cyclin-dependent kinase inhibitor which is being evaluated in the APPRAISE trial, a Phase IIb randomized double-blinded study to evaluate the efficacy and safety of the drug as a third line treatment in patients with NSCLC. Sapacitabine (CYC682), is an orally-available, cell-cycle modulating nucleoside analogue in Phase I clinical trials for the treatment of both solid and haematological tumours. Sapacitabine is currently being evaluated in a Phase I trial in patients with advanced leukemias or myelodysplastic syndromes. In the company’s Aurora kinase inhibitor programme the lead compound CYC116, is an orally-active inhibitor of Aurora kinases A & B and VEGFR2. In December 2006, Cyclacel submitted an IND to the US FDA to begin clinical trials with CYC116. Several additional programs are at an earlier stage.

Role of Cyclacel in the MolDiag-PaCa integrated project:
Cyclacel has generated a number of antibodies to identify proteins involved in influencing the sensitivity of tumour cells to nucleoside analogue drugs such as gemcitabine (Gemzar�; Lilly), the standard therapy for pancreatic cancer, and sapacitabine. Cyclacel will use these antibodies to screen biopsy samples taken from gemcitabine-treated patients with known clinical outcome. If a correlation is observed between clinical response or resistance and protein concentration, this approach could result in the development of biomarkers that identify pancreatic adenocarcinoma’s that are either responsive, or resistant, to gemcitabine, and consequently help to guide the use of nucleoside analogue drugs to produce improved clinical responses for pancreatic cancer.

Group members involved
  • Dr Ian Fleming – research scientist, translational biology
  • Dr Simon Green – head of translational biology

Cyclacel Limited,
1 James Lindsay Place
Dundee, DD1 5JJ
United Kingdom
Tel. +44 1382 206062
FAX: +44 1382 206067

Prof. Aldo Scarpa
Dipartimento di Patologia
Università di Verona
Strada Le Grazie, 8
37134  Verona, Italia

Tel. +39-045-8124.043
Fax. +39-045-8027.136
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

1. Wagner M, Seitz U, Buck A, Neumaier B, Schultheiß S, Bangerter M, Bommer M, Leithäuser F, Wawra E,
Munzert G, Reske SN. 3`[F-18]-Fluoro–3 `- Deoxythymidine ([F-18]–FLT) As Positron Emission Tomomgraphy Tracer for Imaging Proliferation in a Murine B-cell Lymphoma Model and in Human Disease. Cancer Res. 63, 2681–2687, 2003

2. Shen C, Buck AK, Liu X, Winkler M, Reske SN. Gene silencing by Adenovirus delivered siRNA. FEBS Lett. 539, 111 – 114, 2003

3. Buck AK, Schirrmeister H, Hetzel H, von der Heide M, Halter M, Glatting G, Mattfeld T, Liewald F, Reske SN, Neumaier B. F-18 FLT – PET for non-invasive assessment of proliferation in pulmonary nodules. Cancer Res 62, 3331 – 3334, 2002

4. Bunjes D, Buchmann I, Dunker C, Seitz U, Kotzerke J, Wiesneth M, Dohr D, Stefanic M, Buck AK, Harsdorf S, Glattin G, Grimminger W, Karakas T, Munzert G, Döhner H, Bergmann L,Reske SN. Rhenium–188–labeled anti–66 (a,b,c,e) monoclonal antibody to intensify conditioning regimen prior to stem cell transplantation for patients with high risk acute myeloid leukemia or myelodysplastic syndrome. Results of a phase I – II study. Bood 98, 565 – 572, 2001

5. Friesen C, Herr I, Krammer PH, Debatin K.-M. Involvement of CD 95 (Apo1/Fasreceptor/ligand system in drug induced apoptosis in leukemia cells. Nat. Med. 2, 574 – 577, 1996

1. J.P. von Kries, G. Winbeck, C. Asbrand, T. Schwarz-Romond, N. Sochnikova, A. Dell�ro, J. Behrens and W. Birchmeier “Hot spots in beta-catenin for interactions with LEF-1, conductin and APC” Nature Structural Biology 2000, 7, 800-807.

2. M. Barth, R. Fischer, R. Brock, J. Rademann “Reversible cross-linking of hyperbranched polymers: A strategy for the combinatorial decoration of multivalent scaffolds” Angew. Chem. 2005, 117, 1584-1588; Angew. Chem. Int. Ed. 2005, 44, 1560-1563.

3. J. Bauer, J. Rademann „Hydrophobically assisted switching phase synthesis: The flexible combination of solid-phase and solution-phase reactions employed for oligosaccharide preparation” J. Am. Chem. Soc. 2005, 127, 7296-7297.

4. M. Manger, M. Scheck, H. Prinz, J.-P. von Kries, T. Langer, K. Saxena, H. Schwalbe, A. Fürstner, J. Rademann, H. Waldmann “Discovery of Mycobacterium tuberculosis Protein Tyrosine Phosphatase A (MptpA) Inhibitors Based on Natural Product Inspired and Fragment Based Approaches“ ChemBioChem 2005, 6, 1749-1753.

5. J. Rademann, S. Weik et al. “1,2-Diamines for the treatment of Alzheimer´s disease” Patentanmeldung EP 04012182.4 der Böhringer Ingelheim International GmbH am 22.05.2004.